Update on pulmonary Pneumocystis jirovecii infection in non-HIV patients

Medecine et Maladies Infectieuses

Volumn 44, Issue 5, 2014, Pages 185-198

  Roux, A ^a   Gonzalez, F ^b   Roux, M ^c   Mehrad, M ^d   Menotti, J ^e,f   Zahar, J R ^g,h   Tadros, V X ^b   Azoulay, E ^f,i   Brillet, P Y ^c,j   Vincent, F ^k  

^a Pneumologie   (France)

^b Service de réanimation médico chirurgicale HÔpital Avicenne Assistance publique HÔpitaux de Paris AP HP   (France)

^c Service de radiologie   (France)

^d Service des urgences Gustave Roussy   (France)

^e Service de parasitologie mycologie HÔpital Saint Louis Assistance publique HÔpitaux de Paris AP HP   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h UNIVERSITÉ D'ANGERS   (France)

ⁱ Réanimation Médicale Hôpital   (France)

^j UNIVERSITÉ PARIS 13   (France)

^k Centre Hospitalier Intercommunal Le Raincy Montfermeil   (France)

more..

Author keywords

Immunodepression; Pneumocystis jirovecii; Pneumonia

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEMTUZUMAB; ATOVAQUONE; AZATHIOPRINE; BLEOMYCIN; CASPOFUNGIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAPSONE; ETANERCEPT; FLUDARABINE; FLUOROURACIL; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTAMIDINE ISETHIONATE; PREDNISONE; RAPAMYCIN; RITUXIMAB; SULFAMETHOXAZOLE; TACROLIMUS; TEMOZOLOMIDE; TOCILIZUMAB; TRIMETHOPRIM; ANTINEOPLASTIC AGENT; BETA GLUCAN; CORTICOSTEROID; COTRIMOXAZOLE; IMMUNOLOGIC FACTOR; IMMUNOSUPPRESSIVE AGENT;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; BEHCET DISEASE; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CELLULAR IMMUNITY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; FUNGAL COLONIZATION; FUNGUS TRANSMISSION; GIEMSA STAIN; GLIOMA; GRANULOMATOSIS; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INCIDENCE; INFECTION CONTROL; LOADING DRUG DOSE; LUNG LAVAGE; LYMPHATIC LEUKEMIA; LYMPHOCYTOPENIA; LYMPHOMA; MICROSCOPIC POLYANGIITIS; MORBIDITY; MORTALITY; NONHUMAN; OVERALL SURVIVAL; PATIENT RISK; PEMPHIGOID; PEMPHIGUS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; POLYARTERITIS NODOSA; POLYMERASE CHAIN REACTION; POLYMYOSITIS; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; ULCERATIVE COLITIS; BLOOD; COMPLICATION; CONNECTIVE TISSUE DISEASES; DRUG COMBINATION; DRUG EFFECTS; EARLY DIAGNOSIS; IMMUNE DEFICIENCY; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; NEOPLASMS; ORGAN TRANSPLANTATION; PNEUMOCYSTIS INFECTIONS; PNEUMONIA, PNEUMOCYSTIS; POSTOPERATIVE COMPLICATIONS; PROCEDURES; PROGNOSIS; RADIOGRAPHY; SERODIAGNOSIS;

ADRENAL CORTEX HORMONES; ANTINEOPLASTIC AGENTS; BETA-GLUCANS; CONNECTIVE TISSUE DISEASES; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; HIV SERONEGATIVITY; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; NEOPLASMS; ORGAN TRANSPLANTATION; PNEUMOCYSTIS INFECTIONS; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84901988112     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2014.01.007     Document Type: Review

References (46)

1. Ward M.M., Donald F. Pneumocystis carinii pneumonia in patients with connective tissue diseases: the role of hospital experience in diagnosis and mortality. Arthritis Rheum 1999, 42(4):780-789.
2. Reid A.B., Chen S.C., Worth L.J. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011, 24(6):534-544.
3. Carmona E.M., Limper A.H. Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011, 5(1):41-59.
4. Yale S.H., Limper A.H. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71(1):5-13.
5. Sepkowitz K.A. Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 1992, 7(2):114-121.
6. Zahar J.R., et al. Pneumocystis carinii pneumonia in critically ill patients with malignancy: a descriptive study. Clin Infect Dis 2002, 35(8):929-934.
7. Bollee G., et al. Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients. Chest 2007, 132(4):1305-1310.
8. Chung J.B., Armstrong K., Schwartz J.S., Albert D. Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Arthritis Rheum 2000, 43(8):1841-1848.
9. Marie I., et al. Opportunistic infections in polymyositis and dermatomyositis. Arthritis Rheum 2005, 53(2):155-165.
10. Liam C.K., Wang F. Pneumocystis carinii pneumonia in patients with systemic lupus erythematosus. Lupus 1992, 1(6):379-385.
11. Lertnawapan R., Totemchokchyakarn K., Nantiruj K., Janwityanujit S. Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus. Rheumatol Int 2009, 29(5):491-496.
12. Mori S., Sugimoto M. Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(12):2120-2130.
13. Gupta D., Zachariah A., Roppelt H., Patel A.M., Gruber B.L. Prophylactic antibiotic usage for Pneumocystis jirovecii pneumonia in patients with systemic lupus erythematosus on cyclophosphamide: a survey of US rheumatologists and the review of literature. J Clin Rheumatol 2008, 14(5):267-272.
14. Long M.D., et al. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19(5):1018-1024.
15. Limper A.H., Offord K.P., Smith T.F., Martin W.J. Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. Am Rev Respir Dis 1989, 140(5):1204-1209.
16. Monnet X., et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 2008, 12(1):R28.
17. Kanne J.P., Yandow D.R., Meyer C.A. Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection. AJR Am J Roentgenol 2012, 198(6):W555-W561.
18. Vogel M.N., et al. Differences and similarities of cytomegalovirus and pneumocystis pneumonia in HIV-negative immunocompromised patients thin section CT morphology in the early phase of the disease. Br J Radiol 2007, 80(955):516-523.
19. Vogel M.N., et al. HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. Eur J Radiol 2012, 81(6):1315-1320.
20. Demirkazik F.B., Akin A., Uzun O., Akpinar M.G., Ariyurek M.O. CT findings in immunocompromised patients with pulmonary infections. Diagn Interv Radiol 2008, 14(2):75-82.
21. Azoulay E., et al. Polymerase chain reaction for diagnosing pneumocystis pneumonia in non-HIV immunocompromised patients with pulmonary infiltrates. Chest 2009, 135(3):655-661.
22. Linssen C.F., et al. Inter-laboratory comparison of three different real-time PCR assays for the detection of Pneumocystis jiroveci in bronchoalveolar lavage fluid samples. J Med Microbiol 2006, 55(Pt 9):1229-1235.
23. Takahashi T., et al. Pneumocystis carinii carriage in immunocompromised patients with and without human immunodeficiency virus infection. J Med Microbiol 2002, 51(7):611-614.
24. Damiani C., et al. Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii. J Clin Microbiol 2011, 49(5):2000-2002.
25. Karageorgopoulos D.E., et al. Accuracy of beta-D-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 2013, 19(1):39-49.
26. Sax P.E., et al. Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis 2011, 53(2):197-202.
27. Martin S.I., Fishman J.A. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 2013, 13(Suppl. 4):272-279.
28. Tasaka S., Tokuda H. Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies. J Infect Chemother 2012, 18(6):793-806.
29. Green H., Paul M., Vidal L., Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007, 82(9):1052-1059.
30. Wang E.H., et al. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis 2012, 14(5):519-525.
31. Goto N., Oka S. Pneumocystis jirovecii pneumonia in kidney transplantation. Transpl Infect Dis 2011, 13(6):551-558.
32. Chapman J.R., Marriott D.J., Chen S.C., MacDonald P.S. Post-transplant Pneumocystis jirovecii pneumonia--a re-emerged public health problem?. Kidney Int 2013, 84(2):240-243.
33. Rodriguez M., Fishman J.A. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004, 17(4):770-782.
34. Stein C.R., Poole C., Kazanjian P., Meshnick S.R. Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 2004, 10(10):1760-1765.
35. Rodriguez M., Sifri C.D., Fishman J.A. Failure of low-dose atovaquone prophylaxis against Pneumocystis jiroveci infection in transplant recipients. Clin Infect Dis 2004, 38(8):e76-e78.
36. Kovacs J.A., et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984, 100(5):663-671.
37. Kim T., et al. Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. Scand J Infect Dis 2013, 45(6):484-488.
38. Martin S.I., Fishman J.A. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009, 9(Suppl. 4):S227-S233.
39. Lemiale V., Debrumetz A., Delannoy A., Alberti C., Azoulay E. Adjunctive steroid in HIV-negative patients with severe Pneumocystis pneumonia. Respir Res 2013, 14(1):87.
40. Toper C., et al. [Pneumocystis jirovecii pneumonia in non-HIV infected patients: a study of 41 cases]. Rev Pneumol Clin 2011, 67(4):191-198.
41. Ponce C.A., Gallo M., Bustamante R., Vargas S.L. Pneumocystis colonization is highly prevalent in the autopsied lungs of the general population. Clin Infect Dis 2010, 50(3):347-353.
42. Hauser P., Rabodonirina M., Nevez G. Pneumocystis jirovecii genotypes involved in pneumocystis pneumonia outbreaks among renal transplant recipients. Clin Infect Dis 2013, 56(1):165-166.
43. To K.K., et al. Use of nasopharyngeal aspirate for diagnosis of pneumocystis pneumonia. J Clin Microbiol 2013, 51(5):1570-1574.
44. Cregan P., et al. Comparison of four methods for rapid detection of Pneumocystis carinii in respiratory specimens. J Clin Microbiol 1990, 28(11):2432-2436.
45. Ribes J.A., Limper A.H., Espy M.J., Smith T.F. PCR detection of Pneumocystis carinii in bronchoalveolar lavage specimens: analysis of sensitivity and specificity. J Clin Microbiol 1997, 35(4):830-835.
46. Seah C., et al. Comparison of the FXG: RESP (Asp+) real-time PCR assay with direct immunofluorescence and calcofluor white staining for the detection of Pneumocystis jirovecii in respiratory specimens. Med Mycol 2012, 50(3):324-327.